Q4 2025 Cytosorbents Corp Earnings Call Transcript
Key Points
- CytoSorbents Corp (CTSO) achieved a 4% increase in full-year 2025 sales revenues, reaching $37.1 million, driven by strong international market performance.
- The company reported strong gross margins of 71% for the full year and 74% in the fourth quarter, attributed to manufacturing efficiencies.
- CytoSorbents Corp (CTSO) has made significant progress with its DrugSorb-ATR program, advancing through the FDA regulatory process and aligning for a more streamlined resubmission.
- The PuriFi initiative, aimed at expanding access and utilization, has placed over 100 units globally, enhancing treatment accessibility in regions with limited dialysis infrastructure.
- The company has lowered its cost structure and strengthened its balance sheet, establishing a realistic path to cash flow breakeven in the second half of 2026.
- Sales in Germany declined by 10% to $11.8 million, reflecting the near-term impact of restructuring efforts.
- Operating expenses remained relatively flat at $41.2 million, with increased SG&A costs and a $500,000 restructuring charge impacting financials.
- The initial de novo submission for DrugSorb-ATR was denied by the FDA, requiring further alignment and resubmission efforts.
- The company experienced a net loss of $14.2 million for 2025, with an adjusted EBITDA loss of $10.5 million.
- Q4 2025 revenue growth was modest at 1% year over year, with an 8% decline on a constant currency basis, indicating challenges in maintaining momentum.
Good afternoon, ladies and gentlemen. Welcome to the Cytosorbents fourth-quarter and 2025 full-year earnings conference call.
(Operator Instructions) This call is being recorded on Wednesday, March 25, 2026.
I would now like to turn the conference over to Pete Mariani, Chief Financial Officer. Please go ahead.
Thank you, [Vincent]. Good afternoon, everyone. Welcome to Cytosorbents' fourth-quarter and full-year 2025 conference call.
Joining me today is Dr. Phillip Chan, our Chief Executive Officer.
Before I turn the call over to Phil, I'd like to remind listeners that, during the call, management's prepared remarks may contain forward-looking statements, which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions. Therefore, the company claims protection under the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Actual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
